Scienture Holdings
Update in progressSCNX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryPharmaceutical Retailers
Scienture Holdings, Inc. is a pharmaceutical company focused on developing and commercializing treatments for central nervous system and cardiovascular diseases in the United States. Its pipeline includes SCN-102, an oral liquid losartan for hypertension, diabetic nephropathy, and stroke risk reduction in hypertensive patients with LVH; SCN-104, a multi-dose dihydroergotamine injection pen; SCN-106, a fibrin-binding thrombolytic; and SCN-107, a long-acting non-opioid analgesic for postoperative pain. Based in Commack, NY.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.08
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Shankar Hariharan Ph.D.
- Employees4
- Websitescienture.com
Identifiers
- ISINUS80880X1046
- FIGIBBG000RNLYM7
- CUSIP80880X104
- CIK0001382574